Pharma and Biotech Daily: Your Morning Dose of Industry Breakthroughs
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Glaukos, a medical technology company, has received FDA approval for its drug-releasing eye implant to treat glaucoma. This product is expected to revolutionize glaucoma treatment by addressing noncompliance with eye drops. Freenome, another medical technology company, has started a study of a blood test for lung cancer. The test could potentially serve as an alternative to CT imaging, which exposes patients to radiation. Tandem, a diabetes management platform, has completed the US launch of its revamped platform called Tandem Source. The platform combines the features of the company's legacy offerings with new data reports. In the wake of the Philips recall, two US senators are urging a review of FDA medical device oversight. The senators claim that Philips did nothing while patients suffered due to their sleep apnea devices. Medtronic has received approval for its pulsed field ablation (PFA) treatment for atrial fibrillation. PFA is considered a safer alternative to radiofrequency and cryoablation, and other companies like Boston Scientific and Johnson & Johnson are also pursuing the PFA market.The North Carolina Attorney General has sued HCA over degraded care quality at Mission Health. The lawsuit blames HCA for staffing and service shortages at the hospital.CMS has sent a letter to health plans and pharmacy benefit managers (PBMs) urging them to ease up on independent pharmacies. The letter asks payers to implement special payment arrangements with pharmacies before a new policy takes effect that could reduce upfront payments to pharmacies.CVS, Geisinger, and other healthcare organizations have signed a pledge committing to responsible use of artificial intelligence (AI) in healthcare.Nasdaq has ruled that Veradigm will not be delisted from the exchange as long as it complies with financial reporting requirements.Biogen receives positive recommendation from European regulators for its gene editing treatment Casgevy, while the clearance for Biogen's Skyclarys is uncertain.Novartis veteran Jay Bradner joins Amgen as its new chief scientific officer and head of R&D.The FDA expands the use of cancer drug Welireg to treat advanced kidney cancer.Fewer biotech companies are going public after a record run, but Fractyl Health becomes the first company in nearly a month to join the IPO queue.Moderna's cancer vaccine data leads to a share rally, with speculation that the company and partner Merck could seek approval before completing phase 3 testing.Patent protection will expire for many multibillion-dollar medicines this decade, prompting large pharma companies to find new products and markets.European regulators push for approval of CRISPR drugs.AstraZeneca and AbbVie are criticized by Elizabeth
Pharma and BioTech Daily
en-usDecember 15, 2023
